Evidence map›Paper›PMID 41507178›Full record

ArticleNature communications2026

METTL3 abrogation promotes glioma progression through regulating the ISG15-FASN axis-mediated lipid metabolism in macrophages.

Huilong Yin, Xiaoyi Yu, Chenglong Hu, Yuhang Yang, Mengke Wang, Yating Xing, Baile Zuo, Chenxing Zhang, Weilong Yang, Yitong Li and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Huilong Yin *Henan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, China. hlyin@xxmu.edu.cn.ORCID http://orcid.org/0000-0002-1046-4787
Xiaoyi Yu *Henan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, China.
Chenglong Hu *Henan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, China.
Yuhang Yang *Henan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, China.
Mengke Wang *Henan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, China.
Yating XingHenan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, China.
Baile ZuoHenan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, China.
Chenxing ZhangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Immunology, Fourth Military Medical University, Xi'an, Shaanxi, China.
Weilong YangDepartment of Neurosurgery, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Yitong LiHenan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, China.
Zhuoya YinHenan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, China.
Lijun ZhaoHenan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, China.
Haijun MaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Yu ChenThe Second Affiliated Hospital of Xinxiang Medical University, Henan Key Lab of Biological Psychiatry, Xinxiang, Henan, China.ORCID http://orcid.org/0000-0002-4768-9269
Chaowei WangDepartment of Neurosurgery, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Zhuan JuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Immunology, Fourth Military Medical University, Xi'an, Shaanxi, China.
Bowen LiuHenan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, China.ORCID http://orcid.org/0000-0002-7891-1934
Mingming SongDepartment of Neurosurgery, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Xiaoqing ChaiHenan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, China.
Fudi WangThe Second Affiliated Hospital, School of Public Health, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China. fwang@zju.edu.cn.ORCID http://orcid.org/0000-0001-8730-0003
Angang YangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Immunology, Fourth Military Medical University, Xi'an, Shaanxi, China. agyang@fmmu.edu.cn.ORCID http://orcid.org/0000-0002-8854-4672
Rui ZhangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Immunology, Fourth Military Medical University, Xi'an, Shaanxi, China. ruizhang@fmmu.edu.cn.ORCID http://orcid.org/0000-0002-6147-1573

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-associated macrophages (TAMs) constitute a pivotal cellular component within the intricate tumor microenvironment (TME). However, the relationship between the N6-methyladenosine (m6A) and metabolic pattern of TAMs remains poorly understood. Here we show that the m6A methyltransferase METTL3 is conspicuously downregulated in monocyte-derived macrophages from glioblastoma (GBM) patients. Conditional knockout of Mettl3 in myeloid cells augments lipid metabolism and accelerates glioma progression. Furthermore, we found that METTL3 deficiency facilitates fatty acid synthase (FASN) expression, while compromising CD8

Indexed as

Brain NeoplasmsCytokinesFatty Acid Synthase, Type IGlioblastomaGliomaLipid MetabolismMacrophagesMethyltransferasesUbiquitinsAdenosineAnimalsCD8-Positive T-LymphocytesCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHumansAdenosineCytokinesFASN protein, humanFasn protein, mouseFatty Acid Synthase, Type IG1p2 protein, mouseMethyltransferasesMETTL3 protein, humanMettl3 protein, mouseN-methyladenosineUbiquitins

Identifiers

PMID41507178
PMCPMC12873282

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.